Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

Entries for August 2019

08
Arrowhead Pharmaceuticals Inc., has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

[Read More...]